BMY - NYSE

Bristol-Myers Squibb Company

BMY·NYSE

$54.72

-0.42%

HealthcareDrug Manufacturers - General

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$111.74B

EPS3.4600

P/E Ratio15.82

Earnings Date07/30/2026

90.04B

Assets

-3%

3Y-7.0%

5Y-24.0%

10Y+167.0%

71.53B

Total Liabilities

-6%

3Y+9.0%

5Y-11.0%

10Y+312.0%

18.51B

Total Equity

13%

3Y-41.0%

5Y-51.0%

10Y+13.0%

Bristol-Myers Squibb Company Funding & Solvency Profile

BMY · NYSE

Current Assets

Cash & Cash Equivalents10.21B

Net Receivables14.53B

Inventory2.69B

Other Current Assets1.50B

Total Current Assets29 B

Non-Current Assets

Property, Plant & Equipment9.12B

Goodwill & Intangible Assets40.86B

Long-Term Investments2.51B

Other Non-Current Assets2.78B

Total Non-Current Assets14 B

Total Assets

90.04B

Financial Health Analysis

Current Ratio

1.26x

Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.

Debt-to-Equity Ratio

3.87x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

6 B

Positive working capital, but relatively tight. The company should monitor cash flow carefully.

Asset Composition

33% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Bristol-Myers Squibb Company Balance Sheet

BMY • NYSE

Bristol-Myers Squibb Company Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	10.2B	10.3B	11.5B	9.1B	14B	14.5B	12.3B	6.9B	5.4B	4.2B	2.4B	5.6B	3.6B	1.7B	5.8B	5B	7.7B	8B	1.8B	2B
Short-Term Investments	464M	513M	816M	130M	3.2B	1.9B	3B	1.8B	1.4B	2.1B	1.9B	1.9B	939M	1.2B	3B	2.3B	831M	289M	424M	2B
Cash & Short-Term Investments	10.7B	10.9B	12.3B	9.3B	17.2B	16.5B	15.4B	8.8B	6.8B	6.4B	4.3B	7.4B	4.5B	2.8B	8.7B	7.3B	8.5B	8.3B	2.2B	4B
Net Receivables	14.5B	14.4B	15.3B	13.9B	12.5B	10.6B	7.7B	5.7B	6.3B	5.5B	4.3B	3.4B	3.4B	3.1B	3.7B	3.5B	3.2B	3.6B	4.2B	3.2B
Accounts Receivables	9.6B	9B	8.9B	8.2B	8B	7.2B	6.5B	4.6B	4.3B	3.8B	2.9B	2.1B	1.7B	1.7B	2.3B	3.5B	3.2B	3.6B	4.2B	3.2B
Other Receivables	4.9B	5.4B	6.4B	5.8B	4.5B	3.3B	1.2B	1.1B	2B	1.8B	1.4B	1.3B	1.7B	1.4B	1.5B	0.0	0.0	0.0	0.0	0.0
Inventory	2.7B	2.6B	2.7B	2.3B	2.1B	2.1B	4.3B	1.2B	1.2B	1.2B	1.2B	1.6B	1.5B	1.7B	1.4B	1.2B	1.4B	1.8B	2.2B	2.1B
Prepaids	0.0	0.0	0.0	0.0	0.0	1.8B	754M	1.1B	576M	570M	625M	470M	412M	355M	258M	252M	256M	320M	310M	314M
Other Current Assets	1.5B	1.9B	1.6B	1.7B	1.4B	-685M	1.2B	899M	0.0	0.0	0.0	1.8B	9.1B	1.6B	1.2B	1B	611M	703M	1.4B	649M
Total Current Assets	29.4B	29.8B	31.8B	27.3B	33.3B	30.2B	29.4B	17.7B	14.9B	13.7B	10.4B	14.6B	18.9B	9.5B	15.3B	13.3B	14B	14.7B	10.3B	10.3B
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	9.1B	8.4B	8B	7.5B	7B	6.7B	7B	5B	5B	5B	4.4B	4.4B	4.6B	5.3B	4.5B	4.7B	5.1B	5.4B	5.7B	5.7B
Goodwill	21.8B	21.7B	21.2B	21.1B	20.5B	20.5B	22.5B	6.5B	6.9B	6.9B	6.9B	7B	7.1B	7.6B	5.6B	5.2B	5.2B	4.8B	5B	4.8B
Intangible Assets	19.1B	23.6B	27.5B	36.4B	42.8B	53.4B	64B	1.1B	1.2B	1.4B	1.4B	1.8B	2.3B	8.8B	3.1B	3.4B	2.9B	1.2B	1.3B	1.9B
Goodwill & Intangible Assets	40.9B	45.4B	48.7B	57.5B	63.3B	74B	86.5B	7.6B	8.1B	8.3B	8.3B	8.8B	9.4B	16.4B	8.7B	8.6B	8.1B	6B	6.3B	6.7B
Long-Term Investments	2.5B	2.5B	2.5B	2.2B	2.7B	4.5B	4.2B	1.8B	2.5B	2.7B	4.7B	4.4B	3.7B	3.5B	2.9B	2.7B	1.4B	188M	0.0	0.0
Tax Assets	5.4B	4.2B	2.8B	1.3B	1.4B	1.2B	510M	815M	1.6B	3B	2.8B	915M	508M	203M	688M	850M	1.6B	2.1B	2.7B	2.6B
Other Non-Current Assets	2.8B	2.4B	1.4B	1B	1.7B	1.9B	2.5B	2B	1.5B	1B	1.1B	621M	1.4B	904M	824M	1B	907M	1.1B	1.1B	342M
Total Non-Current Assets	60.6B	62.8B	63.4B	69.5B	76.1B	88.3B	100.6B	17.3B	18.7B	20B	21.3B	19.1B	19.7B	26.4B	17.7B	17.8B	17.1B	14.8B	15.8B	15.3B
Total Assets	90B	92.6B	95.2B	96.8B	109.3B	118.5B	129.9B	35B	33.6B	33.7B	31.7B	33.7B	38.6B	35.9B	33B	31.1B	31B	29.5B	26.2B	25.6B
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.8B	6.4B	5.8B	5.2B	4.9B	4.5B	5B	3B	3.1B	2.5B	2.8B	3.4B	3.4B	3B	3.4B	2.6B	2.4B	2.5B	1.4B	1.2B
Accounts Payable	3.6B	3.6B	3.3B	3B	2.9B	2.7B	2.4B	1.9B	2.2B	1.7B	1.6B	2.5B	2.6B	2.2B	2.6B	2B	1.7B	1.5B	1.4B	1.2B
Other Payables	2.3B	2.8B	2.6B	2.1B	1.9B	1.8B	2.5B	1.1B	885M	812M	1.2B	907M	794M	799M	764M	640M	727M	964M	0.0	0.0
Accrued Expenses	484M	572M	349M	321M	378M	434M	493M	69M	4.5B	3.7B	3.1B	2.4B	2.3B	2.7B	3.1B	3.6B	3.4B	3.8B	3.9B	3.7B
Short Term Debt	2.3B	2B	3.1B	4.3B	4.9B	2.3B	3.3B	1.7B	987M	992M	139M	590M	359M	826M	115M	117M	231M	154M	1.9B	187M
Capital Lease Obligations (Current)	202M	181M	162M	136M	169M	164M	133M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	979M	1.5B	1.4B	942M	754M	647M	1.5B	398M	231M	152M	572M	262M	160M	193M	167M	65M	175M	347M	296M	444M
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	172M	83M	762M	1B	1.2B	756M	825M	337M	402M	237M	277M	447M	411M
Other Current Liabilities	14.6B	14.6B	12.8B	12B	11.5B	11.7B	9.3B	5.8B	909M	862M	951M	939M	5.7B	893M	829M	0.0	0.0	0.0	945M	996M
Total Current Liabilities	23.4B	23.8B	22.3B	21.9B	21.9B	19.1B	18.3B	10.7B	9.6B	8.8B	8B	8.5B	12.4B	8.3B	7.8B	6.7B	6.3B	6.7B	8.6B	6.5B
NON-CURRENT LIABILITIES
Long Term Debt	42.9B	47.6B	36.7B	35.1B	39.6B	48.3B	43.4B	5.6B	7B	5.7B	6.6B	7.2B	8B	6.6B	5.4B	5.3B	6.1B	6.6B	4.4B	7.2B
Deferred Revenue (Non-Current)	169M	230M	300M	283M	326M	357M	424M	468M	454M	547M	586M	770M	769M	4B	866M	895M	949M	791M	0.0	0.0
Deferred Tax Liabilities (Non-Current)	222M	369M	338M	2.2B	4.5B	5.4B	6.5B	19M	0.0	0.0	0.0	0.0	73M	383M	107M	0.0	751M	466M	0.0	354M
Other Non-Current Liabilities	3B	2.9B	4.6B	5B	6.1B	6.6B	9B	4.1B	4.7B	2.3B	2.2B	2.3B	2.1B	3B	3B	2.5B	2.1B	2.7B	2.6B	1.5B
Total Non-Current Liabilities	48.1B	52.4B	43.4B	43.8B	51.4B	61.5B	59.9B	10.2B	12.1B	8.5B	9.3B	10.3B	10.9B	14B	9.3B	8.7B	9.9B	10.6B	7B	9.1B
Capital Lease Obligations	2B	1.6B	1.7B	1.4B	1B	997M	805M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	71.5B	76.2B	65.7B	65.7B	73.3B	80.6B	78.2B	20.9B	21.7B	17.4B	17.3B	18.8B	23.4B	22.3B	17.1B	15.4B	16.2B	17.3B	15.6B	15.6B
SHAREHOLDERS' EQUITY
Treasury Stock	-43.6B	-43.7B	-43.8B	-38.6B	-31.3B	-26.2B	-25.4B	-19.6B	-19.2B	-16.8B	-16.6B	-17B	-17.8B	-18.8B	-17.4B	-17.5B	-17.4B	-10.6B	-10.6B	-10.9B
Common Stock	292M	292M	292M	292M	292M	292M	292M	221M	221M	221M	221M	221M	221M	221M	220M	220M	220M	220M	220M	220M
Additional Paid-In Capital	46.4B	46B	45.7B	45.2B	44.4B	44.3B	43.7B	2.1B	1.9B	1.7B	1.5B	1.5B	1.9B	2.7B	3.1B	3.7B	3.8B	2.8B	2.7B	2.5B
Retained Earnings	16.9B	14.9B	28.8B	25.5B	23.8B	21.3B	34.5B	34.1B	31.2B	33.5B	31.6B	32.5B	33B	32.7B	33.1B	31.6B	30.8B	22.5B	19.8B	19.8B
Accumulated Other Comprehensive Income/Loss	-1.5B	-1.2B	-1.5B	-1.3B	-1.3B	-1.8B	-1.5B	-2.8B	-2.3B	-2.5B	-2.5B	-2.4B	-2.1B	-3.2B	-3B	-2.4B	-2.5B	-2.7B	-1.6B	-1.6B
Total Stockholders' Equity	18.5B	16.3B	29.4B	31.1B	35.9B	37.8B	51.6B	14B	11.7B	16.2B	14.3B	14.9B	15.2B	13.6B	16B	15.7B	14.8B	12.2B	10.6B	10B
Total Equity	18.5B	16.4B	29.5B	31.1B	36B	37.9B	51.7B	14.1B	11.8B	16.3B	14.4B	15B	15.2B	13.6B	15.9B	15.6B	14.8B	12.2B	10.6B	10B
Minority Interest	33M	53M	55M	57M	60M	60M	100M	96M	106M	170M	158M	131M	82M	15M	-89M	-75M	-58M	-33M	0.0	0.0
SUMMARY
Total Liabilities & Equity	90B	92.6B	95.2B	96.8B	109.3B	118.5B	129.9B	35B	33.6B	33.7B	31.7B	33.7B	38.6B	35.9B	33B	31.1B	31B	29.5B	26.2B	25.6B
Total Investments	3B	3B	3.3B	2.3B	6B	6.4B	7.2B	3.6B	3.9B	4.8B	6.5B	6.3B	4.7B	4.7B	5.9B	4.9B	2.2B	477M	424M	2B
Total Debt	47.1B	51.2B	41.5B	40.7B	45.6B	51.7B	47.5B	7.3B	8B	6.7B	6.7B	7.8B	8.3B	7.4B	5.5B	5.4B	6.4B	6.7B	6.3B	7.4B
Net Debt	36.9B	40.9B	30B	31.6B	31.6B	37.1B	35.2B	438M	2.5B	2.5B	4.3B	2.3B	4.8B	5.7B	-285M	412M	-1.3B	-1.2B	4.5B	5.4B
Shares Outstanding	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027	2,035,753,027

SEC Filings

BMY - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 08, 2026	May 05, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 30, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	March 25, 2026	May 05, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 11, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 05, 2026	February 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 18, 2025	November 17, 2025	2025	View Filing

Showing 1 to 8 of 8 filings

Related Guides

Blog Categories

Continue your BMY research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.